{"id":36166,"date":"2026-01-28T21:03:16","date_gmt":"2026-01-29T02:03:16","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=36166"},"modified":"2026-01-28T21:06:08","modified_gmt":"2026-01-29T02:06:08","slug":"the-math-of-monopoly","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-math-of-monopoly\/","title":{"rendered":"The math of monopoly"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

The pharmaceutical industry operates on a paradox. A company spends a decade and $2.6 billion to invent a single molecule, only to see its 20-year patent clock expire shortly after the product reaches the market.1<\/sup> For most industries, a patent provides two decades of commercial air cover. For drugmakers, clinical trials and the regulatory process consume half of that time before the first dollar of revenue is ever collected.3<\/sup> This structural delay is why patent term extension (PTE) is the most critical calculation in life sciences.<\/p>\n\n\n\n

A single day of market exclusivity for a blockbuster drug can generate $8.2 million in revenue.1<\/sup> When a patent expires, that revenue typically drops by 80% to 90% within weeks as generic competition takes hold.5<\/sup> Understanding the mechanics of 35 U.S.C. \u00a7 156 is not an academic exercise for lawyers; it is a financial requirement for anyone valuing a pharmaceutical asset or planning a market launch.7<\/sup><\/p>\n\n\n\n

The mechanics of the grand bargain<\/strong><\/p>\n\n\n\n

The current system originated with the Drug Price Competition and Patent Term Restoration Act of 1984, better known as Hatch-Waxman.8<\/sup> This legislation created the modern generic drug market while offering innovators a way to claw back lost time.4<\/sup> It is an innovation-for-exclusivity bargain. In exchange for eventually allowing lower-cost generics, the government allows developers to restore up to five years of patent life lost to the regulatory process.4<\/sup><\/p>\n\n\n\n

This restoration is limited. You cannot extend every patent in a portfolio. You must choose one.8<\/sup> You cannot extend a patent indefinitely. There is a hard cap of 14 years of total post-approval exclusivity.1<\/sup> These rules force companies to be precise with their filings and strategic with their development timelines.<\/p>\n\n\n\n

The high cost of administrative delay<\/strong><\/p>\n\n\n\n

The time lost during the regulatory process is divided into two parts: the testing phase and the approval phase.11<\/sup> The government treats these differently. Time spent in clinical trials\u2014the testing phase\u2014only earns a 50% credit.8<\/sup> Time spent waiting for the FDA to review an application\u2014the approval phase\u2014earns a 100% credit.12<\/sup><\/p>\n\n\n\n

This distinction creates a massive incentive for efficiency. Any day wasted in the testing phase is half a day of lost monopoly. Any day wasted in the approval phase is a full day of lost revenue. DrugPatentWatch<\/strong> data suggests that the average granted PTE adds 1,059 days\u2014nearly three years\u2014to a patent’s term.14<\/sup> On a drug with $3 billion in annual sales, those three years represent $9 billion in protected cash flow.1<\/sup><\/p>\n\n\n\n

Eligibility criteria for patent term restoration<\/strong><\/p>\n\n\n\n

Not every patent qualifies for an extension. The criteria are rigid and strictly enforced by the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA). If you miss a single requirement, the right to extension is permanently lost.15<\/sup><\/p>\n\n\n\n

The unexpired patent requirement<\/strong><\/p>\n\n\n\n

The first hurdle is timing. The patent must be in force at the time the PTE application is submitted.16<\/sup> You cannot resurrect a dead patent. This means companies must monitor their maintenance fees and terminal disclaimers years before they even file for marketing approval.15<\/sup><\/p>\n\n\n\n

The first permitted marketing rule<\/strong><\/p>\n\n\n\n

This is often the most contentious eligibility hurdle. An extension is only available for the “first permitted commercial marketing or use” of a product.8<\/sup> If the active ingredient has been previously approved in any form, the new product is usually ineligible.8<\/sup><\/p>\n\n\n\n

Approval Type<\/strong><\/td>Eligibility Status<\/strong><\/td>Reason<\/strong><\/td><\/tr>
New Molecular Entity (NME)<\/td>Eligible<\/td>First time this active ingredient is on the market.20<\/sup><\/td><\/tr>
New Indication for Existing Drug<\/td>Ineligible<\/td>Active ingredient was previously approved for another use.21<\/sup><\/td><\/tr>
New Dosage Form of Existing Drug<\/td>Ineligible<\/td>Marketing of the active ingredient was already permitted.21<\/sup><\/td><\/tr>
Combination of Two New Ingredients<\/td>Eligible<\/td>At least one ingredient is being approved for the first time.20<\/sup><\/td><\/tr>
New Salt or Ester of Approved Drug<\/td>Varies<\/td>Depends on specific chemical definitions and case law.20<\/sup><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The 60-day filing window<\/strong><\/p>\n\n\n\n

The clock starts ticking the moment the FDA transmits its approval. The patent owner has exactly 60 days to submit the PTE application.9<\/sup> This is a non-extendable statutory deadline.15<\/sup> If the approval arrives after 4:30 P.M. Eastern Time, it is deemed to have been received on the next business day.9<\/sup> Failure to file within this window is fatal to the application.<\/p>\n\n\n\n

The definition of a drug product<\/strong><\/p>\n\n\n\n

The law defines a “drug product” as the active ingredient of a new drug, including any salt or ester of that active ingredient.8<\/sup> This definition has led to significant litigation. In Photocure v. Kappos<\/em>, the court ruled that the USPTO could not deny an extension based on a previously approved “active moiety” if the specific active ingredient in the new drug was chemically different and not a salt or ester of the old one.20<\/sup><\/p>\n\n\n\n

Following this decision, the USPTO and FDA now use a specific three-part test for eligibility:<\/p>\n\n\n\n

    \n
  1. Has the active ingredient been previously approved?<\/li>\n\n\n\n
  2. Has a salt of that ingredient been previously approved?<\/li>\n\n\n\n
  3. Has an ester of that ingredient been previously approved? 20<\/sup><\/li>\n<\/ol>\n\n\n\n

    The math behind the extension<\/strong><\/p>\n\n\n\n

    Calculating the exact length of an extension requires a granular look at the regulatory timeline. The formula is designed to compensate for delay while ensuring the extension does not provide a windfall for the innovator.<\/p>\n\n\n\n

    The regulatory review period formula<\/strong><\/p>\n\n\n\n

    The length of the extension is governed by a formula codified in the U.S. Code.11<\/sup> It involves adding up the days of the testing phase and the approval phase, then applying specific deductions.<\/p>\n\n\n\n

    $$PTE = RRP – PGRRP – DD – \\frac{1}{2}(TP – PGTP)$$<\/p>\n\n\n\n

    In this equation:<\/p>\n\n\n\n